Trial Profile
A Study to Evaluate the Evolution of Lymphocyte Count and it's Association With Progression Free Survival during Sunitinib's First Cycle of Treatment in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2016
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacodynamics; Therapeutic Use
- 20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research
- 20 Apr 2016 New trial record